Effect of Atorvastatin Usage on Patients with Oral squamous cell carcinoma

Phase 3

Recruiting

Conditions: Oral squamous cell carcinoma.
Malignant neoplasm of mouth, unspecified
C06.9

Registration Number: IRCT20230627058596N1

Lead Sponsor: Karaj University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 30

Inclusion Criteria

Patients with oral squamous cell carcinoma
Lack of any other cancer except for oral squamous cell carcinoma
Not using any medication other than the ones prescribed by the surgeon
No drug interaction with atorvastatin if taken concurrently with another medication
Biopsy result of the patient indicates squamous cell carcinoma of the oral mucosa
Having similar histopathology grades
Ability to personally provide written informed consent or to understand and collaborate throughout the study

Exclusion Criteria

Inability or unwillingness to comply with study requirements
Patients who were previously taking statins for any reason
Treatment approach for oral squamous cell carcinoma varies due to its unique challenges
Patients undergoing treatment with anti-HIV drugs
Having a history of other cancers
Smoker patients
Patients who are consumers of a specific medication
Patients with specific systemic diseases
Patients with a history of intolerance to statins
Patients with acute liver failure
Pregnant and lactating women
consumption of another drug that interacts with atorvastatin
consumption of Gemfibrozil medication
consumption of Clarithromycin medication
consumption of Cyclosporine medication
consumption of Itraconazole medication
consumption of Colchicine medication

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Superoxide dismutase marker in the saliva. Timepoint: At the beginning of the study and 1 month after taking the drug. Method of measurement: The variable measurement (Superoxide Dismutase marker) in saliva is performed by qRT-PCR method in the laboratory.;Angiogenesis Factors in the Saliva. Timepoint: At the beginning of the study and 1 month after taking the drug. Method of measurement: The measurement of variables (Angiogenesis Factors) in saliva is carried out using the qRT-PCR method in the laboratory.;Beta-2 microglobulin Factor in the saliva. Timepoint: At the beginning of the study and 1 month after taking the drug. Method of measurement: The measurement of variables (Beta-2 microglobulin Factor) in saliva is carried out using the qRT-PCR method in the laboratory.

Secondary Outcome Measures